Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | RGS4 | P49798 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.48 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205446 | 0.85 | HTR2A (0.43) | RGS4RAD51KDM4EMAPTMEN1 | |
| SCHEMBL2644212 | 0.82 | RGS4 (0.64) | GSK3AGSK3BRGS4CMA1CHRM5 | |
| SCHEMBL11000239 | 0.78 | RGS4 (0.44) | RGS4KDM4EMAPTMEN1KMT2A | |
| SCHEMBL2643077 | 0.74 | GSK3A (0.63) | GSK3AGSK3BCMA1CHRM5CASP3 | |
| SCHEMBL3201607 | 0.73 | RGS4 (0.64) | GSK3AGSK3BRGS4CMA1CHRM5 | |
| SCHEMBL28170522 | 0.72 | GSK3A (0.59) | GSK3AGSK3BCMA1CHRM5CASP3 | |
| SCHEMBL17278181 | 0.70 | GSK3A (0.58) | GSK3AGSK3BCMA1CHRM5CASP3 | |
| SCHEMBL11000171 | 0.70 | AHR (0.43) | RGS4RAD51KDM4EMAPTMEN1 | |
| SCHEMBL8331785 | 0.70 | CMA1 (0.70) | GSK3AGSK3BCMA1CHRM5CASP3 | |
| SCHEMBL2092168 | 0.69 | AHR (0.61) | RAD51CASP3ALDH1A1SENP8SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029740-A1 | AZABICYCLIC COMPOUNDS AS SEROTONIN, DOPAMINE AND NOREPINEPHRINE RE-UPTAKE INHIBITORS | BONANOMI GIORGIO | 2010-02-04 | — | — | US | disclosed |
| US-20100029740-A1 | AZABICYCLIC COMPOUNDS AS SEROTONIN, DOPAMINE AND NOREPINEPHRINE RE-UPTAKE INHIBITORS | BONANOMI GIORGIO | 2010-02-04 | — | — | US | disclosed |
| US-20100029740-A1 | AZABICYCLIC COMPOUNDS AS SEROTONIN, DOPAMINE AND NOREPINEPHRINE RE-UPTAKE INHIBITORS | BONANOMI GIORGIO | 2010-02-04 | — | — | US | disclosed |
| EP-2094657-A1 | AZABICYCLIC COMPOUNDS AS SEROTONINE, DOPAMINE AND NOREPINEPHRINE RE-UPTAKE INHIBITORS | Glaxo Group Limited (GB) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074716-A1 | AZABICYCLIC COMPOUNDS AS SEROTONINE, DOPAMINE AND NOREPINEPHRINE RE-UPTAKE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074716-A1 | AZABICYCLIC COMPOUNDS AS SEROTONINE, DOPAMINE AND NOREPINEPHRINE RE-UPTAKE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029740-A1 | AZABICYCLIC COMPOUNDS AS SEROTONIN, DOPAMINE AND NOREPINEPHRINE RE-UPTAKE INHIBITORS | SLC6A2, SLC6A3, ADRA2C | GSK3A 2113/4885GSK3B 1635/4885RGS4 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.